BCR-ABL Kinase Inhibitors
Customize your policy alerts
Sign up for all Premera Bluecross policy alerts
Know when Premera Bluecross releases new policies or updates existing guidance.
Monitor payer policy activity
This clinical medical policy governs coverage of BCR-ABL kinase inhibitors used in oncology treatment. It is intended for providers and is administered under a prior-authorization program.
The 2016 update removed the Zytiga (abiraterone acetate) step requirement for Xtandi (enzalutamide).
The 2018 update added Yonsa (abiraterone) coverage criteria and incorporated Erleada into updated product labeling and NCCN recommendations.
The 2019 update added coverage criteria for Nubeqa (darolutamide) and expanded Erleada coverage to metastatic castration-sensitive prostate cancer.
The 2021 update added the requirement that generic abiraterone, Zytiga, Yonsa, Nubeqa, and Erleada be used in combination with androgen deprivation therapy.
Added coverage criteria for Abirtega, generic abiraterone, and Zytiga for metastatic androgen pathway modulation-naive or sensitive prostate cancer that is PTEN-deficient when used with capivasertib.
Removed references to non-formulary exception reviews.
Added Akeega coverage for deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer when used with prednisone.
Updated the initial authorization period for all other reviews of oral drugs in the policy from 3 months to 6 months.
Removed radium Ra 223 from this policy because it moved to Policy 6.01.525 Therapeutic Radiopharmaceuticals in Oncology.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.